paracortex and small germinal centres. This was from a patient with systemic vasculitis, a high erythrocyte sedimentation rate, but a low rheumatoid factor titre at the time of biopsy.

We have not yet investigated the possibility that the numbers of CD5 positive B cells are increased in our rheumatoid nodes, but the findings in the case described support our view that rheumatoid lymphadenopathy is likely to be an active part of the disease process. A role for the CD5 B positive cell population in autoimmune diseases has been suggested, based on studies of the Ly-1 positive B cells in murine models of autoimmune diseases, because of their ability to produce autoantibodies which express cross-reactive idiotypes (CRI), encoded by unmutated Ig variable region germ line genes.¹ We have since found (unpublished observations) that increased numbers of plasma cells containing such CRI are associated with rheumatoid factor activity in rheumatoid nodes.^{2,3} It will be interesting to see if surface CRI-bearing B lymphocytes in frozen sections also coexpress CD5, as we have shown that such CRI are highly expressed by CD5 positive B cells in fetal liver and cord blood at a clonal level (unpublished observations).

- Hayakawa K, Hardy RR, Honda M, Herzenberg LA, Steinberg AD. Ly-1 B-cells. Functionally distinct lymphocytes that secrete IgM autoantibodies. *Proc Natl Acad Sci USA* 1984;81:2494-8.
- Mageed RA, Dearlove M, Goodall DM, Jefferis R. Immunogenic and antigenic epitopes of immunoglobulins XVII: Monoclonal antibodies reactive with common and restricted idiotypes to the heavy chain of human rheumatoid factors. *Rheumatol Int* 1986;6:179-83.
- Crowley JJ, Goldfien RD, Schrohenloher RE, et al. Incidence of three cross-reactive idiotypes on human rheumatoid factor para-proteins. *J Immunol* 1988;140:341-18.

Guidelines on oral anticoagulation: second edition

As a consultant haematologist who no longer takes anticoagulant clinics I read with interest the revised guidelines on oral anticoagulation.¹ Probably the guidelines do represent an advance in that they attempt to standardise and simplify advice on desired INR ratios. It is a pity, however, that they still have to be based on a mixture of fact, fiction, and subjectivity. Even in 1990, so much anticoagulant practice is not based on the results of good, well structured clinical trials.

It is necessary to express a contrary view to the statement that patients taking oral anticoagulants when discharged from hospital should normally be referred to consultant haematologists for the control of outpatient treatment. Given the increasing clinical, laboratory, and managerial commitments of a consultant haematologist, anticoagulant control should assume a low priority. In my own experience control of short and long term anticoagulation can be adequately and safely done by general practitioners after a short, simple education programme.

Where specific problems of anticoagulation arise these are referred for consultant opinion and action. In such a system the

patient benefits in that he or she remains clearly under the supervision of his or her general practitioner who is the person supervising all other treatment. The general practitioner is thus in the strongest position to advise the prescribing specialist as to when and if anticoagulant treatment may have become inappropriate or present an undue hazard in any one patient.

It is usually argued that haematologists should be involved in anticoagulant control because "the haematologist does it better". Doubtless, minute precision of INR control may be improved but it is also likely that any other person trained exclusively to take anticoagulant clinics can similarly maintain a high level of INR precision. Whether such precision represents an improvement in the totality of individual patient care for the investment involved is quite another matter. Certainly, as a generalisation, for 90% of patients taking anticoagulants at least 90% of the time there is no major problem; when problems arise they are generally difficult whoever is involved in supervising anticoagulation, although it must be conceded the haematologist in this situation is usually in the best position to give clear advice as to practical short term management.

Despite good intentions most anticoagulant clinics end up as a thoroughly unsatisfactory professional experience. This is because they deliberately set out only to take responsibility for anticoagulation and not other clinical problems, such limited responsibility often confuses the patient and other groups of doctors. If haematologists should be the people running anticoagulation it would be better for them to have sufficient resources to have total specialist control of all such patients and firmly establish policies regarding duration of anticoagulation, indications, etc.

Surely it is time to take a step forward and either actively demythologise anticoagulant treatment and encourage general practitioners to take responsibility for anticoagulant control, with appropriate availability of support and help from consultant haematologists, or aim for haematology services to become fully equipped and resourced to offer a comprehensive anticoagulation service and assume a much greater degree of patient responsibility.

AG SMITH
Department of Haematology,
Royal South Hants Hospital,
Graham Road,
Southampton SO9 4PE

- British Society for Haematology, British Committee for Standardization in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. *J Clin Pathol* 1990;43:177-183

Dr Davidson comments:

I have read Alastair Smith's letter with interest and must say it is because of the concerns he expressed that the British Society for Haematology, through the British Committee for Standardization in Haematology and its Haemostasis and Thrombosis Task Force, felt it necessary to issue guidelines on oral anticoagulation in an attempt to improve standards of clinical practice.

Yes, clinical trials are limited. The recommendations are based on available scientific data, plus a consensus of United Kingdom practice.

Beware of anticoagulant control becoming a "low priority" and "a thoroughly unsatis-

factory professional experience" for a consultant haematologist—not very reassuring to the 0.25 million plus patients receiving this treatment in the United Kingdom.

Rather, "aim for haematology services becoming fully equipped and resourced to offer a comprehensive anticoagulant service and assume much greater degrees of patient responsibility".

I do not think we are really at odds with Alastair Smith. I am sure he wishes to provide these patients with a high standard of service. That is what the guidelines are all about. Maybe he needs to persuade his general manager to provide the necessary resources—the guidelines will help in this respect.

Examination of faeces for bacterial pathogens

We wish to draw your attention to a simple error in the ACP Broadsheet "Examination of faeces for Bacterial Pathogens".¹ In the section dealing with isolation of *Staphylococcus aureus* it is stated that colonies of this organism will appear pink on mannitol salt agar. We suspect that most laboratories will use phenol red as a pH indicator—those using the Oxoid formulation are obliged to do so as it is present in the medium as supplied. Mannitol-fermenting colonies are yellow on phenol red-containing media.

J WIGGINS
IAN HARRISON
Department of Medical Microbiology,
St Bartholomew's Hospital,
London EC1

- Pedler SJ, Orr KE. Examination of faeces for bacterial pathogens. *J Clin Pathol* 1990;43:410-15.

Hypercalcaemia in lymphoma

I was interested in the letter of Drs Ellis, Beck, and Mondal about a case of hypercalcaemia in lymphoma.¹ There seem to have been a few errors and omissions, however, and I wonder whether these can be clarified—namely, (1) the serum calcium in particular and perhaps also the serum phosphate and albumin concentrations were not given; (2) in paragraph 4 the red blood cell count was given as $4.1 \times 10^9/l$: should this have been "white cell count"? If so, what was the differential? (3) In view of the above errors, was this a case report of a Hodgkin's or a non-Hodgkin's lymphoma as the title of the letter could be taken to imply Hodgkin's disease presenting with hypercalcaemia?

J LUCKIT
Department of Haematology,
Mayday University Hospital,
Mayday Hospital,
Mayday Road,
Thornton Heath,
Surrey CR4 7YE

- Ellis RD, Beck PR, Mondal BK. Hodgkin's disease presenting with hypercalcaemia. *J Clin Pathol* 1989;42:1228.

Dr Ellis comments:

I hope the following notes will clarify the points raised by Dr Luckit.

(1) Serum calcium, phosphate, and albumin concentrations were not given. This is an omission on our part which we failed to note on proof reading before submitting the letter to you. Please accept our apologies. The results were as follows: serum calcium (uncorrected) 4.07 mmol/l; phosphate 1.36 mmol/l; albumin 22.0 g/l.

(2) The red blood cell count was correctly reported as $4.1 \times 10^{12}/l$ and not $4.1 \times 10^9/l$. The white cell count was not included in the script, but was $10.9 \times 10^9/l$.

(3) Our paragraph 4 states the diagnosis to be non-Hodgkin's malignant lymphoma. The confusion over diagnosis arises because the title of the original letter by Mayne and Burch was "Hodgkin's disease presenting with hypercalcaemia", which was, therefore, logically used by the Journal as the heading for our letter.

Prognostic index for breast carcinoma: a 22% improvement in the prediction of outcome?

There is a significant arithmetical error in Baak *et al*'s data,¹ leading them to conclude that, compared with using the presence of lymph node metastases as a classifying variable, their prognostic index was more effective in 22% of instances to predict the actual prognoses of their patients. The actual difference is 6.7%.

Baak's prognostic index predicts accurately the outcome in 139 out of 195 patients (71.3%) of cases; lymph node status alone predicts accurately in 126 out of 195 (64.6%) of cases. The difference between the effectiveness of the two methods is thus 6.7%. The discrepancy of 6.7% *vs* 22% is explained as follows:

Data from original paper

Baak's prognostic index	Lymph node status	Distant recurrence		
		Yes	No	Total
<0.6	—	8	91	99
<0.6	+	2	21	23
>=0.6	—	7	13	20
>=0.6	+	20	33	53
Total		37	158	195

21 + 7 = 28 cases where prediction by prognostic index is confirmed and prediction by lymph node status is contradicted.

2 + 13 = 15 cases where lymph node status correctly predicts outcome and the prediction by prognostic index is contradicted.

The number of cases where prognostic index and lymph node status indicate a different prognosis is indeed 23 + 20 = 43 cases (or 22%). The purpose of the comparison, however, is to prove the superiority of the prognostic index over the prediction by lymph node status alone: only an added 13 cases (28 - 15) or an added 6.7% are correctly predicted by the prognostic index, not 22%.

We applied Baak's prognostic index to our own series of 75 patients with breast cancer with known 10 year follow up. We have been particularly careful to count mitoses per 10 high power fields (400 × magnification), as recommended by the authors. In our

experience the dichotomised prognostic index did not improve correct predictions, compared with predictions derived from lymph node status alone. A comparison of the effect of lymph node status alone, *vs* Baak's prognostic index on 10 year survival curves, showed both virtually to overlap with each other.

There are two possible explanations for our inability to reproduce Baak's results. On the one hand, the observed improvement by the dichotomised prognostic index in the prospective study is minor (an increase of 6.7% in accuracy) and therefore difficult to detect with a study of only 75 patients. The other possible explanation is that additional variation has been introduced by our lack of experience with Baak's techniques, a different population, different treatment protocols, and different follow up periods. Both possibilities, however, suggest that the use of Baak's prognostic index is not likely to have much impact in the ability to differentiate patients at greater risk.

GJ LAROYE

Department of Pathology,
Ontario Cancer Institute,
500 Sherbourne Street,
Toronto, Ontario, Canada M4X 1K9

- 1 Van Der Linden JC, Baak JPA, Lindeman J, Hermans J, Meyer CJLM. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. *J Clin Pathol* 1987;40:302-6.

Differential marking of surgical excision planes

Armstrong *et al* have described a novel system for the differential marking of excision planes in screened breast lesions that is aesthetically pleasing, although somewhat laborious.¹ I routinely use a simple procedure which allows surgical excision margins to be identified microscopically. Each block of tissue taken is roughly either a sector or a rectangle, such that only one edge is irregular with an incomplete coating of red cells (the surgical margin) and the other edges are straight and lack this coating (the pathologist's margins). The site of each block is recorded at cut-up according to the orientation of the specimen indicated by the surgeon. This simple procedure facilitates identification of surgical margins without using more sophisticated techniques.^{1,2}

TJ CLARKE

Area Department of Pathology,
Church Lane,
Heavitree,
Exeter, Devon EX2 5DY

- 1 Armstrong JS, Weinzeig IP, Davies JD. Differential marking of excision planes in screened breast lesions by organically coloured gelatins. *J Clin Pathol* 1990;43:604-7.
2 Birch PJ, Jeffrey MJ, Andrews MIJ. Alcian blue: reliable rapid method for marking resection margins. *J Clin Pathol* 1990;43:608-9.

Drs Armstrong and Davies comment:

We appreciate Dr Clarke's ingenious use of red blood cells to show the planes of surgical excision. The very incompleteness of the coating, however, may give rise to doubt as to the exact plane, and whether tissue buckling may have caused the apparent outside edge to simulate the real one. Externally applied

markers overcome this problem. Furthermore, the insertion of marking hooks into the vicinity of impalpable breast lesions only hours before operation frequently causes fresh extravasation of erythrocytes, which is histologically indistinguishable from that later caused by surgery on the true exterior of the specimen. We still think that even lurid henna is preferable for the patient than a haemorrhagic operative field.

BOOK REVIEWS

Connective Tissue in Health and Disease. M Rojkind. (Pp 193; £78.) Wolfe Publishing. 1990. ISBN 0-8493-4161-2

This is the first in a series of books, the stated aims of which are to cover the biology of extracellular matrix components, their effects on gene expression, and their control by cytokines, and to bridge the gap between these basic biological aspects and their implications for disease processes. This first volume contains five chapters, devoted to immunolocalisation of matrix components, animal models of connective tissue disease, non-invasive assays of organ fibrosis, evaluation of hepatic fibrosis by molecular hybridisation, and clinicopathological analysis of pulmonary fibrosis. As is evident, these form a pretty varied group and are unlikely to be of equal interest to the different possible audiences. The text is generally well written (with few typographical errors) and the illustrations are of reasonable quality. Given the rapidly changing nature of this field, it is disappointing that references rarely go beyond mid 1987. Because of its heterogeneous content, this book is unlikely to appeal to anyone but the collagen "fetishist". Perhaps the editor should consider devoting future volumes to single subject areas, such as normal biology, fibrosis, desmoplasia, neoplasia, and so on.

CDM FLETCHER

Surgical Pathology of the Thyroid. Virginia A LiVolsi. Vol 22 in the Series Major Problems in Pathology. (Pp 422; £43.) Harcourt Brace Jovanovich. 1990. ISBN 0-7216-5782-6.

The book is divided into three: non-neoplastic conditions in seven chapters; thyroid tumours in nine; and special diagnostic techniques in three. In addition to detailed discussion of papillary and follicular lesions, medullary and anaplastic carcinoma and lymphomas, the material is specially organised for ease of reference. The chapter headings therefore include granulomas in the thyroid, lymphocytes in the thyroid, fibrosis,